Regenerative Patch Technologies is located in California, developing regenerative medicine products for debilitating retinal diseases. We are currently focused on developing an implant containing retinal pigmented epithelial cells derived from pluripotent stem cells on a specially designed, ultrathin membrane. The implant is intended to replace diseased retinal tissue in patients with age-related macular degeneration.
The implant technology was established using grant funding from the California Institute of Regenerative Medicine (CIRM) which funded work at the University of Southern California, the University of California at Santa Barbara and the California Institute of Technology to develop and preclinically test the product. CIRM has most recently funded the ongoing Phase 1/2a clinical trial being conducted to assess the safety and potential activity of the implant in patients with geographic atrophy.
The implant is exclusively for use within the current clinical trial and not available for other experimental indications or compassionate use at this time.